Literature DB >> 22045753

The diversity of sex steroid action: novel functions of hydroxysteroid (17β) dehydrogenases as revealed by genetically modified mouse models.

Taija Saloniemi1, Heli Jokela, Leena Strauss, Pirjo Pakarinen, Matti Poutanen.   

Abstract

Disturbed action of sex steroid hormones, i.e. androgens and estrogens, is involved in the pathogenesis of various severe diseases in humans. Interestingly, recent studies have provided data further supporting the hypothesis that the circulating hormone concentrations do not explain all physiological and pathological processes observed in hormone-dependent tissues, while the intratissue sex steroid concentrations are determined by the expression of steroid metabolising enzymes in the neighbouring cells (paracrine action) and/or by target cells themselves (intracrine action). This local sex steroid production is also a valuable treatment option for developing novel therapies against hormonal diseases. Hydroxysteroid (17β) dehydrogenases (HSD17Bs) compose a family of 14 enzymes that catalyse the conversion between the low-active 17-keto steroids and the highly active 17β-hydroxy steroids. The enzymes frequently expressed in sex steroid target tissues are, thus, potential drug targets in order to lower the local sex steroid concentrations. The present review summarises the recent data obtained for the role of HSD17B1, HSD17B2, HSD17B7 and HSD17B12 enzymes in various metabolic pathways and their physiological and pathophysiological roles as revealed by the recently generated genetically modified mouse models. Our data, together with that provided by others, show that, in addition to having a role in sex steroid metabolism, several of these HSD17B enzymes possess key roles in other metabolic processes: for example, HD17B7 is essential for cholesterol biosynthesis and HSD17B12 is involved in elongation of fatty acids. Additional studies in vitro and in vivo are to be carried out in order to fully define the metabolic role of the HSD17B enzymes and to evaluate their value as drug targets.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22045753     DOI: 10.1530/JOE-11-0315

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  28 in total

1.  Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.

Authors:  Panu K Luukkonen; Taru Tukiainen; Anne Juuti; Henna Sammalkorpi; P A Nidhina Haridas; Onni Niemelä; Johanna Arola; Marju Orho-Melander; Antti Hakkarainen; Petri T Kovanen; Om Dwivedi; Leif Groop; Leanne Hodson; Amalia Gastaldelli; Tuulia Hyötyläinen; Matej Orešič; Hannele Yki-Järvinen
Journal:  JCI Insight       Date:  2020-03-12

Review 2.  Regulation of 17β-hydroxysteroid dehydrogenases in cancer: regulating steroid receptor at pre-receptor stage.

Authors:  Mirja Rotinen; Joaquín Villar; Ignacio Encío
Journal:  J Physiol Biochem       Date:  2012-02-29       Impact factor: 4.158

3.  Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.

Authors:  Jo Ann Janovick; M David Stewart; Darla Jacob; L D Martin; Jian Min Deng; C Allison Stewart; Ying Wang; Anda Cornea; Lakshmi Chavali; Suhujey Lopez; Shoukhrat Mitalipov; Eunju Kang; Hyo-Sang Lee; Pulak R Manna; Douglas M Stocco; Richard R Behringer; P Michael Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

4.  Structural genomic changes underlie alternative reproductive strategies in the ruff (Philomachus pugnax).

Authors:  Sangeet Lamichhaney; Guangyi Fan; Fredrik Widemo; Ulrika Gunnarsson; Doreen Schwochow Thalmann; Marc P Hoeppner; Susanne Kerje; Ulla Gustafson; Chengcheng Shi; He Zhang; Wenbin Chen; Xinming Liang; Leihuan Huang; Jiahao Wang; Enjing Liang; Qiong Wu; Simon Ming-Yuen Lee; Xun Xu; Jacob Höglund; Xin Liu; Leif Andersson
Journal:  Nat Genet       Date:  2015-11-16       Impact factor: 38.330

Review 5.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Authors:  T Karantanos; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

Review 6.  Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Authors:  Theodoros Karantanos; Christopher P Evans; Bertrand Tombal; Timothy C Thompson; Rodolfo Montironi; William B Isaacs
Journal:  Eur Urol       Date:  2014-10-08       Impact factor: 20.096

Review 7.  Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.

Authors:  P Michael Conn; David C Smithson; Peter S Hodder; M David Stewart; Richard R Behringer; Emery Smith; Alfredo Ulloa-Aguirre; Jo Ann Janovick
Journal:  Pharmacol Res       Date:  2013-12-25       Impact factor: 7.658

8.  Proteomic analysis of lipid droplets from Caco-2/TC7 enterocytes identifies novel modulators of lipid secretion.

Authors:  Frauke Beilstein; Julien Bouchoux; Monique Rousset; Sylvie Demignot
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

9.  Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer.

Authors:  Manish Kohli; Rui Qin; Rafael Jimenez; Scott M Dehm
Journal:  Adv Urol       Date:  2012-08-22

10.  HSD17B7 gene in self-renewal and oncogenicity of keratinocytes from Black versus White populations.

Authors:  Xiaoying Xu; Beatrice Tassone; Paola Ostano; Atul Katarkar; Tatiana Proust; Jean-Marc Joseph; Chiara Riganti; Giovanna Chiorino; Zoltan Kutalik; Karine Lefort; Gian Paolo Dotto
Journal:  EMBO Mol Med       Date:  2021-06-29       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.